AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7547843 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal
Number of subjects: 31
Study 7547843 — intervention group
Group type: EXPERIMENTAL
Intervention: Both test meals
Number of subjects: 31
Study 2011259 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramiracetam (up to 4,000 mg)
Number of subjects: 10
Study 2011259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 548219 — intervention group
Group type: EXPERIMENTAL
Intervention: Right visual hemifield presentation
Number of subjects: 0
Study 548219 — intervention group
Group type: EXPERIMENTAL
Intervention: Left visual hemifield presentation
Number of subjects: 0
Study 548219 — intervention group
Group type: EXPERIMENTAL
Intervention: Block presentation of visual fields
Number of subjects: 0
Study 548219 — intervention group
Group type: EXPERIMENTAL
Intervention: Signal detection procedures
Number of subjects: 0
Study 31251351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (AA) treatment at a dosage of 20 mg/kg before cardiac catheterization.
Number of subjects: 0
Study 31251351 — intervention group
Group type: COMPARATOR
Intervention: Control arm (not specified in detail).
Number of subjects: 0
Study 27886686 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative warfarin therapy
Number of subjects: 0
Study 27886686 — intervention group
Group type: COMPARATOR
Intervention: Postoperative warfarin therapy
Number of subjects: 0
Study 25488505 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 52
Study 25488505 — intervention group
Group type: COMPARATOR
Intervention: Treatment Control Condition (TCC)
Number of subjects: 52
Study 24063360 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Number of subjects: 150
Study 24063360 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SC)
Number of subjects: 150
Study 17076695 — intervention group
Group type: EXPERIMENTAL
Intervention: S-3304 800 mg
Number of subjects: 32
Study 17076695 — intervention group
Group type: EXPERIMENTAL
Intervention: S-3304 1600 mg
Number of subjects: 32
Study 17076695 — intervention group
Group type: EXPERIMENTAL
Intervention: S-3304 2400 mg
Number of subjects: 32
Study 17076695 — intervention group
Group type: EXPERIMENTAL
Intervention: S-3304 3200 mg
Number of subjects: 32
Study 17076695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 17076695 — intervention group
Group type: EXPERIMENTAL
Intervention: S-3304 (all doses)
Number of subjects: 32
Study 15023580 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia patients
Number of subjects: 153
Study 15023580 — intervention group
Group type: EXPERIMENTAL
Intervention: Siblings of schizophrenia patients
Number of subjects: 153
Study 15023580 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 153
Study 11003605 — intervention group
Group type: EXPERIMENTAL
Intervention: 15(S)-HETE
Number of subjects: 25
Study 11003605 — intervention group
Group type: EXPERIMENTAL
Intervention: LTB(4) production
Number of subjects: 25
Study 11003605 — intervention group
Group type: EXPERIMENTAL
Intervention: Macrophages and neutrophils
Number of subjects: 25
Study 9487416 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (glucose 25g i.v. with insulin 10 units i.v.)
Number of subjects: 70
Study 9487416 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (50 mmol of 8.4% sodium bicarbonate infusion)
Number of subjects: 70
Study 9487416 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (0.5mg of salbutamol i.v. in 50mls 5% dextrose)
Number of subjects: 70
Study 9487416 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment D (combination of treatments A and B)
Number of subjects: 70
Study 9487416 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment E (combination of treatment B and C)
Number of subjects: 70
Study 9487416 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment F (combination of treatments A and C)
Number of subjects: 70
Study 9487416 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment G (combination of treatments A, B, and C)
Number of subjects: 70
Study 8368735 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCL alone
Number of subjects: 384
Study 8368735 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCL plus low dose cyclophosphamide
Number of subjects: 384
Study 8368735 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCL treatment
Number of subjects: 384
Study 8368735 — intervention group
Group type: COMPARATOR
Intervention: Historical control group
Number of subjects: 384
Study 3530861 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS) tablets
Number of subjects: 75
Study 3530861 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (R)
Number of subjects: 75
Study 30715010 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (tourniquet and suction drainage)
Number of subjects: 151
Study 30715010 — intervention group
Group type: COMPARATOR
Intervention: Group B (no tourniquet or suction drainage)
Number of subjects: 151
Study 30715010 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (tourniquet only)
Number of subjects: 151
Study 30382190 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetes
Number of subjects: 6823
Study 30382190 — intervention group
Group type: COMPARATOR
Intervention: HbA1c<53 mmol/mol
Number of subjects: 6823
Study 30382190 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher illness duration in diabetes subsample
Number of subjects: 6823
Study 30382190 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of type 2 diabetes, depressive symptoms, and BMI
Number of subjects: 6823
Study 30382190 — intervention group
Group type: EXPERIMENTAL
Intervention: Apnoea
Number of subjects: 6823
Study 26574551 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to e-cigarette advertisements
Number of subjects: 0
Study 26574551 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ad exposure)
Number of subjects: 0
Study 25171459 — intervention group
Group type: EXPERIMENTAL
Intervention: Shikani optical stylet (SOS)
Number of subjects: 120
Study 25171459 — intervention group
Group type: EXPERIMENTAL
Intervention: GlideScope video laryngoscope (GVL)
Number of subjects: 120
Study 25171459 — intervention group
Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 120
Study 21551317 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release (ER) propiverine 45 mg
Number of subjects: 24
Study 21551317 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release (IR) propiverine 30 mg
Number of subjects: 24
Study 21551317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich meal before administration of propiverine
Number of subjects: 24
Study 21551317 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-rich meal effect on ER propiverine
Number of subjects: 24
Study 19280455 — intervention group
Group type: EXPERIMENTAL
Intervention: RightWay Café game
Number of subjects: 0
Study 19280455 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16625377 — intervention group
Group type: EXPERIMENTAL
Intervention: Ileocaecal interposition (ICI)
Number of subjects: 30
Study 16625377 — intervention group
Group type: COMPARATOR
Intervention: Colon-J-pouch (CJP)
Number of subjects: 30
Study 16625377 — intervention group
Group type: COMPARATOR
Intervention: CJP
Number of subjects: 30
Study 16625377 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI
Number of subjects: 30
Study 16625377 — intervention group
Group type: EXPERIMENTAL
Intervention: ICI and CJP
Number of subjects: 30
Study 15117517 — intervention group
Group type: EXPERIMENTAL
Intervention: In-home test weights for measuring milk intake
Number of subjects: 0
Study 15117517 — intervention group
Group type: COMPARATOR
Intervention: No in-home test weights (control group)
Number of subjects: 0
Study 15117517 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 0
Study 12486585 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐(+)‐ketamine/propofol (K/P)
Number of subjects: 145
Study 12486585 — intervention group
Group type: COMPARATOR
Intervention: alfentanil/propofol (A/P)
Number of subjects: 145
Study 9485094 — intervention group
Group type: EXPERIMENTAL
Intervention: zoledronate (200 or 400 microg)
Number of subjects: 28
Study 7630148 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS 1102 (2 mg)
Number of subjects: 8
Study 7630148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2774588 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepharanthine (50 mg intravenously every day during postoperative chemotherapy)
Number of subjects: 34
Study 2774588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no administration of Cepharanthine)
Number of subjects: 34
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen 100 mg
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen 200 mg
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen 400 mg
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen 25 mg every 24 hours
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen 50 mg every 24 hours
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen 100 mg every 12 hours
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen with food
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Milled benoxaprofen (19 micron)
Number of subjects: 0
Study 303115 — intervention group
Group type: EXPERIMENTAL
Intervention: Benoxaprofen (various doses)
Number of subjects: 0
Study 31812127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 126
Study 31812127 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine controlled-release (carbamazepine-CR)
Number of subjects: 126
Study 31667519 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-reduced diet
Number of subjects: 0
Study 31667519 — intervention group
Group type: COMPARATOR
Intervention: Control diet (isocaloric diet with BCAAs)
Number of subjects: 0
Study 28031191 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled diet approximating habitual food intake for 2 weeks
Number of subjects: 153
Study 26193059 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise: 5 days/week, 400 or 600 kcal/session, 10 months
Number of subjects: 74
Study 24979880 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate 80 mg/kg
Number of subjects: 160
Study 24979880 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 160
Study 21195260 — intervention group
Group type: EXPERIMENTAL
Intervention: Quad-helix or expansion plate
Number of subjects: 35
Study 21195260 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal occlusion)
Number of subjects: 35
Study 19690194 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalin‐fixed, paraffin‐embedded (FFPE) tissue samples
Number of subjects: 3278
Study 19690194 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry tests for p53 and SMAD4
Number of subjects: 3278
Study 19690194 — intervention group
Group type: EXPERIMENTAL
Intervention: TERT immunohistochemistry test
Number of subjects: 3278
Study 19690194 — intervention group
Group type: EXPERIMENTAL
Intervention: Messenger RNA retrieval for expression profiling
Number of subjects: 3278
Study 17309451 — intervention group
Group type: EXPERIMENTAL
Intervention: CDP + BPO (clindamycin phosphate 1% + benzoyl peroxide 5%)
Number of subjects: 148
Study 17309451 — intervention group
Group type: COMPARATOR
Intervention: ERY + Zn (erythromycin 4% + zinc acetate 1.2%)
Number of subjects: 148
Study 15225185 — intervention group
Group type: EXPERIMENTAL
Intervention: PROM test (rapid dipstick method for IGFBP-1 detection)
Number of subjects: 151
Study 15225185 — intervention group
Group type: COMPARATOR
Intervention: Nitrazine test
Number of subjects: 151
Study 15225185 — intervention group
Group type: COMPARATOR
Intervention: Amniotic Fluid Index (AFI) measured by four-quadrant method
Number of subjects: 151
Study 11322638 — intervention group
Group type: EXPERIMENTAL
Intervention: Orengedoku‐to (Huanglian‐Jie‐Du‐Tang) granules (7.5 g daily)
Number of subjects: 54
Study 11322638 — intervention group
Group type: EXPERIMENTAL
Intervention: Kakkon‐to (Ge‐Gen‐Tang) granules (7.5 g daily)
Number of subjects: 54
Study 11322638 — intervention group
Group type: EXPERIMENTAL
Intervention: Sairei‐to (Cai‐Ling‐Tang) granules (9.0 g daily)
Number of subjects: 54
Study 11322638 — intervention group
Group type: COMPARATOR
Intervention: Control group (no herbal medicine)
Number of subjects: 54
Study 9823342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 39
Study 9823342 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol + Dorzolamide
Number of subjects: 39
Study 9823342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 7524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (3 g/375 mg every six hours)
Number of subjects: 331
Study 7524798 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin (600 mg every six hours) plus gentamicin (2.5 mg to 5.0 mg/kg every eight to 12 hours)
Number of subjects: 331
Study 7524798 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam
Number of subjects: 331
Study 7524798 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin plus gentamicin
Number of subjects: 331
Study 3286535 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase
Number of subjects: 32
Study 3286535 — intervention group
Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 32
Study 28969467 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD screening during months 1 to 12 postpartum
Number of subjects: 152
Study 28969467 — intervention group
Group type: EXPERIMENTAL
Intervention: PPD screening through 12 months postpartum
Number of subjects: 152
Study 26860809 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose-enriched inulin (10g daily for 2 months)
Number of subjects: 46
Study 26860809 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24627419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 30 mg once daily
Number of subjects: 84
Study 24627419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 70 mg 3 times weekly
Number of subjects: 84
Study 24627419 — intervention group
Group type: EXPERIMENTAL
Intervention: Mipomersen 200 mg once weekly
Number of subjects: 84
Study 24627419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 23747584 — intervention group
Group type: EXPERIMENTAL
Intervention: self-help continuing care
Number of subjects: 90
Study 23747584 — intervention group
Group type: COMPARATOR
Intervention: assessment-only
Number of subjects: 90
Study 19918189 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary abciximab delivered using the ClearWay RX catheter
Number of subjects: 150
Study 19918189 — intervention group
Group type: COMPARATOR
Intervention: Intravenous abciximab
Number of subjects: 150
Study 18596303 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention for 4 weeks
Number of subjects: 68
Study 18596303 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68
Study 15746682 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost 1 mg up to 3 times daily for 2 days
Number of subjects: 80
Study 15746682 — intervention group
Group type: COMPARATOR
Intervention: Gemeprost alone
Number of subjects: 80
Study 15746682 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (IMN) 40 mg in addition to gemeprost
Number of subjects: 80
Study 14728309 — intervention group
Group type: EXPERIMENTAL
Intervention: SysBank knowledge base
Number of subjects: 0
Study 14728309 — intervention group
Group type: EXPERIMENTAL
Intervention: SysBank
Number of subjects: 0
Study 11045887 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8 mg
Number of subjects: 12
Study 11045887 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg
Number of subjects: 12
Study 8923992 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 1744
Study 8923992 — intervention group
Group type: COMPARATOR
Intervention: Open cholecystectomy (OC)
Number of subjects: 1744
Study 1307234 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplement (containing 12 vitamins including 0.8 mg of folic acid)
Number of subjects: 4753
Study 1307234 — intervention group
Group type: COMPARATOR
Intervention: Trace-element supplement (containing copper, manganese, zinc, and a very low dose of vitamin C)
Number of subjects: 4753
Study 6364774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU, d‐alpha‐tocopheryl acetate, by mouth twice daily for 20 weeks)
Number of subjects: 35
Study 6364774 — intervention group
Group type: COMPARATOR
Intervention: Placebo (by mouth twice daily for 20 weeks)
Number of subjects: 35
Study 6364774 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 35
Study 6364774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 31524943 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + rifampicin
Number of subjects: 300
Study 31524943 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline + 10% povidone iodine
Number of subjects: 300
Study 31524943 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 300
Study 28438655 — intervention group
Group type: EXPERIMENTAL
Intervention: Foundational articles
Number of subjects: 101
Study 28438655 — intervention group
Group type: COMPARATOR
Intervention: Functional classics
Number of subjects: 101
Study 28438655 — intervention group
Group type: COMPARATOR
Intervention: Endovascular classics
Number of subjects: 101
Study 28438655 — intervention group
Group type: COMPARATOR
Intervention: Spine classics
Number of subjects: 101
Study 25519041 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxanes plus bevacizumab plus capecitabine (TBX)
Number of subjects: 432
Study 25519041 — intervention group
Group type: COMPARATOR
Intervention: Taxanes plus bevacizumab (TB)
Number of subjects: 432
Study 23263773 — intervention group
Group type: EXPERIMENTAL
Intervention: LY2599506
Number of subjects: 0
Study 21303197 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback using the Peak Brain Happiness Trainer(™) system
Number of subjects: 12
Study 19827527 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with quinapril (23.3 ± 9.8 mg) and indapamide (1.5 mg)
Number of subjects: 60
Study 16670131 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAP-BAND System)
Number of subjects: 80
Study 16670131 — intervention group
Group type: COMPARATOR
Intervention: Very-low-calorie diets, pharmacotherapy, and lifestyle change
Number of subjects: 80
Study 12916451 — intervention group
Group type: EXPERIMENTAL
Intervention: Open questions
Number of subjects: 0
Study 12916451 — intervention group
Group type: COMPARATOR
Intervention: Closed questions
Number of subjects: 0
Study 12916451 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication skills training
Number of subjects: 0
Study 12916451 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocity indices
Number of subjects: 0
Study 10325261 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone (0.05, 0.1, 0.25 and 0.5 mg per day) with continuous micronized oestradiol 2 mg daily for six treatment cycles
Number of subjects: 0
Study 10325261 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone-treated endometrium
Number of subjects: 0
Study 10325261 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimegestone (various doses)
Number of subjects: 0
Study 8609099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release albuterol 8 mg, twice-daily (b.i.d.)
Number of subjects: 35
Study 8609099 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral slow-release albuterol 8 mg, once daily at night
Number of subjects: 35
Study 8609099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 1960379 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 90
Study 7202827 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 80 mg
Number of subjects: 16
Study 7202827 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizolemide 100 mg
Number of subjects: 16
Study 7202827 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6388334 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (Tetracyclines)
Number of subjects: 0
Study 28884308 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual pharmacological therapy plus 2-week spa therapy
Number of subjects: 50
Study 28884308 — intervention group
Group type: COMPARATOR
Intervention: Usual pharmacological therapy alone
Number of subjects: 50
Study 27002953 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel continued into surgery (group B)
Number of subjects: 39
Study 27002953 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel discontinued 1 week before surgery (group A)
Number of subjects: 39
Study 24991964 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrinsic network architecture during task performance
Number of subjects: 0
Study 24991964 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-evoked network architecture
Number of subjects: 0
Study 24991964 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting-state network architecture
Number of subjects: 0
Study 22622405 — intervention group
Group type: EXPERIMENTAL
Intervention: KB001 3 mg/kg
Number of subjects: 39
Study 22622405 — intervention group
Group type: EXPERIMENTAL
Intervention: KB001 10 mg/kg
Number of subjects: 39
Study 22622405 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 22622405 — intervention group
Group type: EXPERIMENTAL
Intervention: KB001
Number of subjects: 39
Study 20160047 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg lersivirine plus 20 ml Maalox Max
Number of subjects: 0
Study 20160047 — intervention group
Group type: COMPARATOR
Intervention: 750 mg lersivirine alone
Number of subjects: 0